Krka
Krka, d.d., a prominent pharmaceutical company headquartered in Slovenia (SI), has established itself as a leader in the global healthcare industry since its founding in 1946. With a strong presence in Europe and beyond, Krka focuses on the development, production, and marketing of prescription pharmaceuticals, over-the-counter products, and animal health medications. Renowned for its commitment to quality and innovation, Krka offers a diverse range of products, including generic medicines and proprietary brands, which are distinguished by their efficacy and affordability. The company has achieved significant milestones, including numerous awards for its research and development efforts, solidifying its position in the competitive pharmaceutical landscape. With a robust market presence and a dedication to sustainability, Krka continues to contribute to the advancement of healthcare worldwide.
DitchCarbon Score
How does Krka's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Krka's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Krka's reported carbon emissions
In 2022, Krka, headquartered in Slovenia (SI), reported a carbon footprint of approximately 6,280 kg CO2e per employee. This figure reflects the company's commitment to monitoring its environmental impact, although specific Scope 1 and Scope 2 emissions data were not disclosed. The company has not set any formal reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. Over the past few years, Krka's employee-related carbon emissions have shown a decreasing trend, with 6,900 kg CO2e per employee in 2021 and 11,780 kg CO2e in 2020. This indicates a potential focus on improving operational efficiency and reducing the carbon intensity of its workforce. Despite the absence of specific reduction targets, Krka's ongoing efforts to track and report its emissions demonstrate a commitment to sustainability within the pharmaceutical industry. The data presented is not cascaded from any parent organization, ensuring that the figures are reflective of Krka's own operations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Krka is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
